Global Bacterial Partnering 2012-2018: Deal trends, players and financials
Global Bacterial Partnering 2012 to 2018 provides the full collection of Bacterial disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012.
Trends in Bacterial partnering deals Financial deal terms for headline, upfront and royalty by stage of development Bacterial partnering agreement structure Bacterial partnering contract documents Top Bacterial deals by value Most active Bacterial dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.
The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Bacterial dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Bacterial dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Bacterial deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Bacterial dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Bacterial deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Bacterial partnering deals by specific Bacterial target announced since 2012. The chapter is organized by specific Bacterial therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Bacterial partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Bacterial partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Bacterial technologies and products.
Global Bacterial Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Bacterial trends and structure of deals entered into by leading companies worldwide.
Global Bacterial Partnering 2012 to 2018 includes:
Trends in Bacterial dealmaking in the biopharma industry since 2012 Analysis of Bacterial deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Bacterial deal contract documents Comprehensive access to over 3500 Bacterial deal records The leading Bacterial deals by value since 2012 Most active Bacterial dealmakers since 2012
The report includes deals for the following indications: Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
In Global Bacterial Partnering 2012 to 2018, available deals and contracts are listed by:
Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Bacterial Partnering 2012 to 2018 report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise bacterial rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How aresalesand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?